Most Read Articles

Annual influenza vaccination is recommended for all persons ≥6 months old without a contraindication. Influenza vaccines available this season in the US are listed in Table 3.

The injectable GIP/GLP-1 receptor agonist tirzepatide (Mounjaro – Lilly), which was approved by the FDA in 2022 for treatment of type 2 diabetes, has now been approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. Tirzepatide is also available as Zepbound for chronic weight management and for treatment of obstructive sleep apnea in adults with obesity.

View the Comparison Table: Some Drugs for Migraine Prevention

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Insulin icodec (Awiqli – Novo Nordisk), an ultra-long-acting basal human insulin analog, has been approved by the FDA for once weekly treatment of type 2 diabetes. Two once-daily, long-acting insulin analogs are available in the US: glargine U300 (Toujeo) and degludec U100 and U200 (Tresiba). Insulin icodec has been available in Canada since 2024.

Indications for preventive treatment of migraine include frequent or severe attacks, contraindications to or toxicity with acute treatments, and patient preference. Drugs for acute treatment of migraine were reviewed in a previous issue.

The FDA has approved daraxonrasib (Rasonque – Revolution Medicines), an oral RAS GTPase multi-selective inhibitor, for treatment of metastatic pancreatic adenocarcinoma, regardless of RAS G12 mutation status, in adults who received at least one prior systemic therapy or are not candidates for multi-agent systemic therapy. It is the first RAS GTPase inhibitor to be approved in the US for any indication.

Lunsotogene parvec (Otarmeni – Regeneron), an adeno-associated viral vector-based gene therapy, has received accelerated approval from the FDA for treatment of severe-to-profound or profound sensorineural hearing loss (any frequency >90 decibels hearing level [dB HL]) in patients with confirmed variants in both copies of the otoferlin (OTOF) gene. It is the first gene therapy to be approved in the US for genetic hearing loss.

The kinase inhibitor gedatolisib (Revtorpyk – Celcuity) has been approved by the FDA for use in combination with fulvestrant, with or without the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance), for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation in adults who had disease progression on or after at least one prior line of endocrine therapy for metastatic disease.

Vusolimogene oderparepvec (Tudriqev – Replimune), a genetically-modified herpes simplex virus type 1 (HSV-1) oncolytic therapy, has been granted accelerated approval by the FDA for use in combination with the programmed death receptor-1 (PD-1)-blocking antibody nivolumab (Opdivo) for treatment of unresectable advanced cutaneous melanoma in adults who had disease progression on a PD-1-blocking antibody-based regimen. About 30-50% of patients develop primary resistance to anti-PD-1 therapy. The oncolytic viral therapy talimogene laherparepvec (Imlygic) was approved in 2015 for treatment of patients with melanoma recurrence postsurgery.